8-hydroxy-efavirenz, the primary metabolite of the antiretroviral drug efavirenz, stimulates the glycolytic flux in cultured rat astrocytes

Neurochemical Research

Volumn 38, Issue 12, 2013, Pages 2524-2534

  Brandmann, Maria ^a   Nehls, Uwe ^a   Dringen, Ralf ^a  

^a UNIVERSITY OF BREMEN   (Germany)

Author keywords

Astrocytes; Glycolysis; HIV; Lactate; Mitochondria

Indexed keywords

8 HYDROXYEFAVIRENZ; ABACAVIR; ANTIRETROVIRUS AGENT; DRUG METABOLITE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LACTIC ACID; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; ROTENONE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN CELL; CELL STIMULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLYCOLYTIC FLUX; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT;

ANIMALS; ASTROCYTES; BENZOXAZINES; CELLS, CULTURED; GLYCOLYSIS; MITOCHONDRIA; OXYGEN CONSUMPTION; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84890267203     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1165-2     Document Type: Article

References (51)

1. Tan IL, McArthur JC (2012) HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs 26:123-134
2. Mirza A, Rathore MH (2012) Human immunodeficiency virus and the central nervous system. Semin Pediatr Neurol 19:119-123
3. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet AM (2010) Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 49:17-45
4. Volberding PA, Deeks SG (2010) Antiretroviral therapy and management of HIV infection. Lancet 376:49-62
5. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzsardini G, Thomas DL, Jacobsen DM, Volberding PA (2012) Antiretroviral treatment of adult HIV infection 2010 Recommentationsof the international AIDS society-USA panel. JAMA 304:321-333
6. Liner KJ 2nd, Ro MJ, Robertson KR (2010) HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 7:85-91
7. Mothobi NZ, Brew BJ (2012) Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 25:4-9
8. Brandmann M, Tulpule K, Schmidt MM, Dringen R (2012) The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. J Neurochem 120:78-92
9. Arend C, Brandmann M, Dringen R (2013) The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes. Neurochem Res 38:732-741
10. Bumpus NN (2011) Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. Toxicol Appl Pharmacol 257:227-234
11. Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN (2013) Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid. Drug Metab Dispos 41:422-429
12. De Clercq E (2004) Antiviral drugs in current clinical use. J Clin Virol 30:115-133
13. Jena A, Sachdeva RK, Sharma A, Wanchu A (2009) Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Phys AIDS Care (Chic) 8:318-322
14. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J (2003) Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 4:62-66
15. Fumaz CR, Munoz-Moreno JA, Molto J, Negredo E, Ferrer MJ, Sirera G, Perez-Alvarez N, Gomez G, Burger D, Clotet B (2005) Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 38:560-565
16. Cespedes MS, Aberg JA (2006) Neuropsychiatric complications of antiretroviral therapy. Drug Saf 29:865-874
17. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids 15:71-75
18. Streck EL, Ferreira GK, Scaini G, Rezin GT, Goncalves CL, Jeremias IC, Zugno AI, Ferreira GC, Moreira J, Fochesato CM, Romao PR (2011) Non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine inhibit cytochrome C oxidase in mouse brain regions. Neurochem Res 36:962-966
19. Streck EL, Scaini G, Rezin GT, Moreira J, Fochesato CM, Romao PRT (2008) Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metab Brain Dis 23:485-492
20. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z (2010) Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 38:1218-1229
21. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, Christ DD (1999) Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 27:1319-1333
22. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E (2010) Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 88:676-684
23. Tovar-y-Romo LB, Bumpus NN, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ (2012) Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 343:696-703
24. Dienel GA (2013) Astrocytic energetics during excitatory neurotransmission: what are contributions of glutamate oxidation and glycolysis? Neurochem Int 63:244-258
25. Hirrlinger J, Dringen R (2010) The cytosolic redox state of astrocytes: maintenance, regulation and functional implications for metabolite trafficking. Brain Res Rev 63:177-188
26. Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, Stout RF Jr, Spray DC, Reichenbach A, Pannicke T, Pekny M, Pekna M, Zorec R, Verkhratsky A (2012) Glial cells in (patho)physiology. J Neurochem 121:4-27
27. Hamprecht B, Löffler F (1985) Primary glial cultures as a model for studying hormone action. Methods Enzymol 109:341-345
28. Tulpule K, Hohnholt M, Hirrlinger J, Dringen R (2014) Primary cultures of astrocytes and neurons as model systems to study the metabolism and metabolite export from brain cells. In: Waagepetersen H, Hirrlinger J (eds) Neuromethods: Brain Energy Metabolism (in press)
29. Dringen R, Kussmaul L, Hamprecht B (1998) Detoxification of exogenous hydrogen peroxide and organic hydroperoxides by cultured astroglial cells assessed by microtiter plate assay. Brain Res Brain Res Protoc 2:223-228
30. Scheiber IF, Schmidt MM, Dringen R (2010) Zinc prevents the copper-induced damage of cultured astrocytes. Neurochem Int 57:314-322
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein Measurement with the Folin Phenol Reagent. J Biol Chem 193:265-275
32. +-dependent isocitrate dehydrogenases are expressed in cultured rat neurons, astrocytes, oligodendrocytes and microglial cells. J Neurochem 86:605-614
33. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85
34. Liddell JR, Zwingmann C, Schmidt MM, Thiessen A, Leibfritz D, Robinson SR, Dringen R (2009) Sustained hydrogen peroxide stress decreases lactate production by cultured astrocytes. Neurosci Res 87:2696-2708
35. Schmidt MM, Dringen R (2009) Differential effects of iodoacetamide and iodoacetate on glycolysis and glutathione metabolism of cultured astrocytes. Front Neuroenergetics 1:1-10
36. Blas-Garcia A, Apostolova N, Ballesteros D, Monleon D, Morales JM, Rocha M, Victor VM, Esplugues JV (2010) Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 52:115-125
37. Scheiber IF, Dringen R (2011) Copper accelerates glycolytic flux in cultured astrocytes. Neurochem Res 36:894-903
38. Tulpule K, Dringen R (2012) Formate generated by cellular oxidation of formaldehyde accelerates the glycolytic flux in cultured astrocytes. Glia 60:582-593
39. Chow YW, Leong CL, Chow HL, Hooi LS (2007) Lactic acidosis in HIV patients receiving highly active antiretroviral therapy. Med J Malaysia 62:78-80
40. Luther EM, Koehler Y, Diendorf J, Epple M, Dringen R (2011) Accumulation of PVP- coated silver nanoparticles by cultured astrocytes. Nanotechnology 22:375101
41. Heaton RK, Franklin, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C, Group H (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3-16
42. Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neurovirol 18:388-399
43. Pauwels PJ, Opperdoes FR, Trouet A (1985) Effects of antimycin, glucose deprivation, and serum on cultures of neurons, astrocytes, and neuroblastoma cells. J Neurochem 44:143-148
44. Boffito M, Pillay D, Wilkins E (2006) Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. Int J Clin Pract 60:1098-1106
45. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, McCutchan JA, Simpson DM, Haubrich R, Ellis R, Grant I, Group C (2011) Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 66:354-357
46. Goicoechea M, Best B (2007) Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother 8:371-382
47. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300
48. Kaddoumi A, Choi SU, Kinman L, Whittington D, Tsai CC, Ho RJY, Anderson BD, Unadkat JD (2007) Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of Nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos 35:1459-1462
49. Pellerin L, Magistretti PJ (2012) Sweet sixteen for ANLS. J Cereb Blood Flow Metab 32:1152-1166
50. Goldman SA, Pulsinelli WA, Clarke WY, Kraig RP, Plum F (1989) The effects of extracellular acidosis on neurons and glia in vitro. J Cereb Blood Flow Metab 9:471-477
51. Testai FD, Gorelick PB (2010) Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Arch Neurol 67:19-24